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Perspective
Pharmacovigilance involves the continual monitoring of drugs which are already in the market, for detection, assessment, understanding and prevention of short-term and long-term adverse effects of medicines.
1 It is essential for ensuring that there is an appropriate balance between the risks and benefits of drugs used in community and hospital practice. When drugs are approved for marketing, knowledge regarding their safety is incomplete. The clinical trials that assess a drug's efficacy and safety profile use a sample size that is inadequate to detect uncommon, albeit important adverse drug reactions or drug interactions. Furthermore, the participants in clinical trials are often selected through inclusion/exclusion criteria and may not adequately represent patients in clinical practice who have multiple medical problems and are using numerous concomitant medical products. As a result, the subsequent population experience with a product will be much broader than that derived from the clinical trials. 2 Serious ADRs are the sixth leading cause of death in the United States, 3 and result in billions of dollars in health care costs. 4, 5 Failure to effectively manage drug safety data and the pharmacovigilance processes can affect patient well-being, jeopardize a drug's potential for benefit, and create a regulatory nightmare.
The sensitivity and specificity of signal detection by a postmarketing surveillance system is an important issue but the time for detection is also critical, in order to keep the number of persons at risk to a minimum. Ideally one could consider trying to move towards predicting adverse events before they actually occur in a patient population. 6 With advancements in information technologies, there has been the emergence of new opportunities for national 7, 8 and international 9, 10 collaborations that can enhance postmarking surveillance programs and increase drug safety. 11, 12 The General Practice Research Database (GPRD) in the UK is a good example of a national database that has been used for pharmacovigilance (drug safety epidemiology) studies. 7 The GPRD collects population-based data, which because of its remarkable size provide an opportunity to follow large patient cohorts using specific drugs. The database includes both outpatient and inpatient clinical information for individual patients. The Uppsala Monitoring Center (UMC) is an example for an international collaboration to establish a harmonized postmarketing surveillance database. 9 The system is based on the exchange of adverse reaction information between national drug monitoring centers in 60 countries. The information is transferred, stored, and retrieved in a timely and secure way through the Internet. The UMC database collectively contains over 2 million records with a large number of data fields.
The development of large population-based administrative databases has addressed several of the limitations that were associated with other types of data sources, previously used in pharmacovigilance systems, including problems with small sample size, wide variations in sample data, and possible misclassification of outcomes. There are several examples of signal detection that have been reported by GPRD, UMC and other populationbased administrative databases, which have been beneficial for developing new safety recommendations for therapeutics. In 1997, Garcia Rodriguez LA et al. 13 used the data from GPRD to demonstrate that treating elderly patients with the combination of amoxycillin and clavulanic acid could significantly lead to acute liver injury compared to other patients. The results of this study along with other evidence changed the recommendations for therapeutic application of the combination of amoxycillin and clavulanic acid in the elderly.
14 Even before Merck withdrew Vioxx (rofecoxib) from the market in 2004, 15 in 2001, the data from UMC indicated that rofecoxib has significantly greater renal toxicity than celecoxib or traditional NSAIDs, which may potentially increase the risk for serious cardiac and/or cerebrovascular events. 16 In addition to advancements in information technology, there are also new opportunities to improve pharmacovigilance risk management. The application of new technological solutions, such as genomics can enhance the sensitivity and specificity of signal detection, and can even be used to predict signals. [17] [18] [19] The development of new molecular tools and computational methods for the study of human genome has led to enormous anticipations about the implications of geno-mic discoveries. [20] [21] [22] Pharmacogenomics explores the genome-based variations among individuals in response to therapeutics. 23 Evidence is available to demonstrate that many of the inter-patient differences involving pharmacological and toxicological reactions to drugs are caused by genetic polymorphisms. Understanding the role of genetic polymorphisms in drug response may augment drug efficacy and reduce adverse effects by tailoring medication use to a patient's genetic makeup. 24, 25 For example, determining the genetic variant of the thiopurine S-methyltransferase (TPMT) in patients with leukemia, autoimmune disorders and organ transplant recipients who are treated with mercaptopurine and thioguanine is recommended for clinical practice, 26 because patients with specific variants of this enzyme are in a higher risk of drug-induced myelosuppression. 27 As adverse drug responses to mercaptopurine and thioguanine can be fatal, there has been significant attention focused on the use of genetic testing before therapy so that the drug dose can be adjusted in the patients at risk. 28 Another example is testing for variation in CYP2C9 before the use of the anticoagulant warfarin for risk assessment. 29 This drug requires careful dosing and close follow-up because of risk of bleeding, which is significantly associated with genetic variability in CYP2C9. 30 Built-in biological components in the postmarketing surveillance programs may also increase the probability and validity of the signal detection, 6, 31 and this approach may also reduce subsequent risk by minimizing the lag time between the introduction of the therapy to population and subsequent signal detection. The SAS Institute (http://www.sas. com/) is proposing the integration of pharmacogenomic components into the SAS technology for pharmacovigilance and signal detection. 6 The company foresees combining automated signal detection processes with additional criteria for signal detection, which include biochemical, epidemiological, pharmacokinetic, toxicological, and pharmacogenomic data. This would enhance signal detection or even provide signal prediction. The field of pharmacogenomics can improve health care delivery by providing pivotal information to aid the drug safety surveillance systems. 32, 33 The following hypothetical scenario can exemplify the potential role of genomics to enhance signal detection in postmarketing surveillance systems. Assume the goal of the system is to evaluate the safety of a COX-2 inhibitor through a database. In the first stage, the analysis of the database reveals that the drug-event (e.g. myocardial infarction) incidence rate for the COX-2 inhibitor and a NSAID (as control) are 85/1 180 090 and 695/ 10 000 700 respectively (Risk Ratio (RR) ¼ 1.03, 95% Confidence Interval (95% CI) ¼ 0.84, 1.26). Now assume that there is a candidate gene with SNP allele frequencies of AA ¼ 46%, AG ¼ 43% and GG ¼ 11%, which previous investigators have suspected of playing a role in the adverse events arising from COX-2 inhibitor use. In the second stage, the database is analyzed with the incorporation of genomics information (the genomic strata incorporated in the analysis). The drug-event incidence rates for the COX-2 inhibitor in each genetic stratum in comparison with the NSAID (control) demonstrate that risk ratio for GG stratum (RR ¼ 1.97, 95% CI (1.25, 3.10), incidence rate ¼ 18/ 129 810) is significantly higher than that for AA stratum (RR ¼ 0.93, 95% CI (0.65, 1.30), incidence rate ¼ 35/ 542 840) and AG stratum (RR ¼ 0.91, 95% CI (0.65, 1.25), incidence rate ¼ 32/507 435). Therefore, integration of genomic data in pharmacovigilance databases can enhance the signal detection for drug safety to discriminate subgroups of patients who are at the higher risk of adverse events.
Worldwide, there are several DNA sequence databases and repositories for genomic application in operations such as GenBank 34 (North America), EMBL 35 (Europe), and DDBJ 36 (Asia). These comprehensive databases encompass publicly available DNA sequences for a large number of organisms including human beings. The National Bioethics Advisory Commission (NBAC) has previously identified and described the magnitude, diversity, and use of human biological materials in the United States. 37 The NBAC has described the samples or specimens that are stored in the existing genetic and tissue databanks as falling into four categories. They are 'unidentified, identified, unlinked, and coded'. The size and detail of sample collections varied considerably, ranging from formal, highly organized repositories to materials stored in a researcher's laboratory freezer. Individual collections of human biological materials ranged from fewer than 200 to more than 92 million individual quantities of material. NBAC estimated that as of 1998, more than 282 million specimens of human biological materials were stored in the United States, accumulating at a rate of more than 20 million cases per year. The NBAC has recognized that in order to conduct genetic linkages or association studies would require the samples in these collections to be more precise and harmonized.
Beyond the importance of harmonization of data both within the genomic banks (the NBAC report) and within the administrative health record databases (such as GPRD), it is also critical that data for the complete triad of exposure (drugs), outcome (adverse events), and gene (pharmacogenomics) be included in an integrated pharmacovigilance system that combines genomic components with the health records. According to the fundamental principles of clinical epidemiology, accounting for the effect of modulators (e.g. genes) and confounders is essential in order to correctly explore the issue of causality (e.g. the adverse events driven from therapeutics), and this would also apply to the case of pharmacovigilance. The triad of data are required for evaluating mutual interactions (between drug, gene, and adverse event) at the level of the individual patient and at a common point in time, in order to avoid biases driven by time-dependent intra-individual variations. Genomic variability consists of two components, inter-individual variability
Pharmacovigilance in a genomic era P Farahani and M Levine (polymorphism among patients in the population) and intra-individual variability by time (longitudinal variability in one patient in the course of disease and recovery). As an example, b-adrenergic receptor gene regulation, signaling, and function can all become progressively altered during the course of chronic heart failure, 38 demonstrating the necessity in obtaining exposure, outcome, and genomic data at the level of the individual at the same point. Also, the reversal of cardiac remodeling by b-blocker therapy (exposure) are attributed to time dependent biological effects on cardiomyocytes (gene expression profile), which may recover contractility of the myocardium (outcome). 39 Further, the magnitude of the recovery of left ventricle, which is determined by ejection fraction (outcome) may be proportional to the degree of the gene expression correction in a chronological pattern. 40 Unfortunately, the current trend for the parallel expansion of two international networks, one for genomics and the other for pharmacovigilance, cannot provide evidencebased information to facilitate translating genomic information into clinical application, and to develop clinical practice recommendations for drug safety. Harmonization that occurs within the two networks is insufficient, and the goal must be to achieve harmonization between these two networks.
Recently, there have been an enormous initiative to boost the harmonization and collaboration for establishing genomic databases that correspond with clinical, social, and laboratory data. The Public Population Project in Genomics (P3G) and the Pharmacogenetics and Pharmacogenomics Knowledge Based (PharmGKB) Project are two good examples to demonstrate models for collaboration and harmonization between genomic and administrative databases. P3G is an international consortium to promote collaboration and harmonization for public projects in population genomics. 41 This project has attempted to provide international coordination and harmonization for data collection, production, and storage that is necessary to use this information in developing effective health care solutions. This project is intended to explore the interaction between genes, environment, lifestyle, and disease. The Pharmacogenetics and Pharmacogenomics Knowledge Based (PharmGKB) Project is a nationwide collaborative research consortium in the United States. 42 The PharmGKB database is a central repository for genomic data, molecular and cellular phenotype data, and clinical phenotype data. This project will collect data on gene-drug, gene-disease, and genedrug-disease associations.
It is crucial that policy makers promote a convergence between global genomic databases and global postmarking surveillance networks to achieve synergy. If an international organization such as WHO would foster and coordinate the regulation and the function of both the genomic and postmarketing surveillance databases, this would be an improvement on the patchwork of small genome repositories that can be redundant and have varying quality.
A multidisciplinary approach calls for enormous efforts from different parties (governments, regulatory agencies, and private sector) across continents. There are several issues that should be addressed regarding a harmonized global network. Establishing a harmonized global network will require the passing of new national and international legislations and regulations. 43, 44 The integrated global networks (combined drug safety and genomics) will need to scientifically address the concerns regarding the complexity of the design for such a large database, the scope to which associated phenotypic and environmental data should be collected, the cost and economic framework of the database, the issues related to the database management, the public-private sector participation and interaction, the intellectual property issues concerning discoveries, and the adherence to standards and regulations. 45, 46 An additional level of concerns derive from the societal aspects, including the ethical and legal issues associated with privacy, confidentiality, and data protection, as well as the accessibility and availability of the system for all individuals in the society and all geographical regions. 46, 47 Although a detailed discussion on the aforementioned issues and the proposed solutions is crucial, it is however, beyond the scope of this commentary.
In summary, the application of pharmacogenomics in postmarketing surveillance systems requires integrated action involving a variety of groups. Policy frameworks from regulatory bodies need to be developed; investment and funding of research from government and the private sector need to be enhanced; networking and communications between different disciplines need to be continued; an integrated surveillance system needs to be established; education for the public, health care providers, and researchers needs to be improved; practice guidelines and recommendations relating to pharmacogenomics research should be developed. Success in this field will require a prudent and scientific approach, with the avoidance of hype.
